I'm game to go along with this
Wegovy had some big setbacks but still way ahead of Tirzepatide obesity indication. Wegovy effect is real and that's why the company ain't worried about the billions raked for Ozempic sales. Bonus and messaging have shifted away from it cuz it sells itself. If Wegovy not on market by the summer the stock will take a big hit and the investors will want some firings. If all else on track, "restructuring" DCS to OCS.
The single greatest reason for layoffs will be the underperforming Rybelsus. This "oral scientific breakthrough" that patients find inconveniencing (4 oz water, no other drugs or food for 30 mins, take it fasting only), low efficacy for Endo to care about, time consuming and also low efficacy for PCP to care (esp compared to Ozempic), low Medicare and Medicaid coverage, no CV indication till 2025, and no listing in any diabetes guideline is crushing and will keep hitting this company. dumb to keep blaming Covid. Ozempic had booming sales well into that pandemic. Look at jardiance and farxiga increasing sales with new indications. Added to hospital formularies, Cardiologists use it and tell PCP to do the same. Rybelsus sales will get better but won't hit blockbuster projections in the US. Did we even make up in sales what we spent in the priority voucher for Rybelsus?!? So they'll squeeze everyone.
